A group of researchers has published an article in Clinical Case Reports describing successful reversal of induced paralysis in a human volunteer after administration of intranasal aerosolized neostigmine, an anticholinesterase. According to the article, IV administration of anticholinesterases is the first-line treatment for neurotoxic snakebite when antivenom is … [Read more...] about Intranasal aerosol proposed as treatment for snakebite
Medical
Patient advocacy group asks FDA to maintain prescription status for corticosteroid nasal sprays
Patient advocacy organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has released data from a survey of patients using intranasal corticosteroid sprays showing that 90% of the patients surveyed "said they prefer to rely on medical professionals to diagnose and manage their conditions." According to the organization, the survey also showed that more … [Read more...] about Patient advocacy group asks FDA to maintain prescription status for corticosteroid nasal sprays
Pulmatrix initiates Phase 1B study of DPI for COPD
Pulmatrix has initiated a Phase 1B study of its PUR0200, an inhaled LAMA for the treatment of COPD, the company says. PUR0200 is a lactose-free formulation created using the company's iSPERSE particle engineering technology. Pulmatrix Chief Scientific Officer David Hava said, “PUR0200 has demonstrated outstanding performance in preclinical evaluation models of … [Read more...] about Pulmatrix initiates Phase 1B study of DPI for COPD
Activaero system used in new Ablynx Phase 1 studies of inhaled Nanobody for RSV
Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx's Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from a previous Phase 1 study of the drug were announced in September 2012. Ablynx President and CEO Edwin Moses recently … [Read more...] about Activaero system used in new Ablynx Phase 1 studies of inhaled Nanobody for RSV
Study shows feasibility of nasal dosing of diazepam during seizure
Acorda Therapeutics announced results from a clinical study of the pharmacokinetics, safety, and tolerability of its diazepam nasal spray for the treatment of cluster seizures in epilepsy patients at the recent International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE). Over the course of the study, 31 … [Read more...] about Study shows feasibility of nasal dosing of diazepam during seizure
Arikace meets primary endpoint in Phase 3 study
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study's primary endpoint. The company also announced that the FDA has granted Arikace Fast Track and Qualified Infectious Disease Product … [Read more...] about Arikace meets primary endpoint in Phase 3 study
Inspiro reports positive results for Inspiromatic DPI study
Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary endpoints. According to the company, the randomized, crossover, double blind study, which involved 30 asthmatic children, demonstrated … [Read more...] about Inspiro reports positive results for Inspiromatic DPI study
Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company's GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher doses of oral pirfenidone. Genoa said that it would present data at an upcoming pulmonary … [Read more...] about Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
Johnson & Johnson developing ketamine nasal spray for depression
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company's pipeline drugs in a document dated April 16, 2013 on the J&J website. Reportedly, J&J's nasal spray is a formulation of esketamine, an isomer of … [Read more...] about Johnson & Johnson developing ketamine nasal spray for depression
New nasal research consortium “The Oz Nose Project” announced
A new consortium described as a "series of conceptual research projects in the area of nasal physiology, function and drug delivery" that "aims to enhance understanding in the area of upper respiratory tract disorders and develop methodological approaches that can be utilized via the wider scientific community" has been announced. Researchers involved in the … [Read more...] about New nasal research consortium “The Oz Nose Project” announced